nach oben

memo - Magazine of European Medical Oncology

Tipp

Is thymus and activation-regulated chemokine a forgotten diagnostic and minimal residual disease marker in classical Hodgkin lymphoma?

A chronological narrative literature review

verfasst von: Wael Khair, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Summary

Objective

The objective of this paper is to elucidate the role of thymus and activation-regulated chemokine (TARC) as a marker of treatment response in classical Hodgkin lymphoma (cHL).

Background

Most patients diagnosed with cHL can be cured today but about 20–30% still experience refractoriness/relapse. Positron emission tomography (PET) has been shown to not be the optimal tool, since 15–20% of patients relapse despite negative PET. There is an unmet need for new markers to predict response to treatment as early as possible and for surveillance of patients after completion of treatment to allow prompt intervention in case of signs of evolving relapse.

Methods

Literature regarding the role of thymus and activation-regulated chemokine (TARC) in cHL was searched and 13 studies between 2005 and 2020 with a total of 1433 patients were identified and reviewed.

Conclusion

Reviewed studies suggest that TARC is one of the most promising markers, which can be used to improve treatment outcome in cHL.

Vorheriger Artikel Ponatinib and palbociclib combination in TKI-resistant CML—A case report

Lang N, Crump M. PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma. Ther Adv Hematol. 2020; https://doi.org/10.1177/2040620720914490. CrossRefPubMedPubMedCentral

Voltin CA, Mettler J, Grosse J, Dietlein M, Baues C, Schmitz C, et al. FDG-PET imaging for Hodgkin and diffuse large B‑cell lymphoma – an updated overview. Cancers (Basel). 2020;12(3):601. https://doi.org/10.3390/cancers12030601. CrossRef

Imai T, Yoshida T, Baba M, Nishimura M, Kakizaki M, Yoshie O. Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector. J Biol Chem. 1996;271(35):21514–21. https://doi.org/10.1074/jbc.271.35.21514. CrossRefPubMed

Zijtregtop EAM, van der Strate I, Beishuizen A, Zwaan CM, Scheijde-Vermeulen MA, Brandsma AM, et al. Biology and clinical applicability of plasma thymus and activation-regulated chemokine (TARC) in classical Hodgkin lymphoma. Cancers (Basel). 2021;13(4):884. https://doi.org/10.3390/cancers13040884. CrossRef

Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem. 1997;272(23):15036–42. https://doi.org/10.1074/jbc.272.23.15036. CrossRefPubMed

van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T‑cell infiltratein Hodgkin’s lymphoma. Am J Pathol. 1999;154(6):1685–91. https://doi.org/10.1016/S0002-9440(10)65424-7. CrossRefPubMedPubMedCentral

Niens M, Visser L, Nolte IM, van der Steege G, Diepstra A, Cordano P, et al. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol. 2008;140(5):527–36. https://doi.org/10.1111/j.1365-2141.2007.06964.x. CrossRefPubMed

Weniger MA, Küppers R. Molecular biology of Hodgkin lymphoma. Leukemia. 2021;35(4):968–81. https://doi.org/10.1038/s41375-021-01204-6. CrossRefPubMedPubMedCentral

Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103(5):1755–62. https://doi.org/10.1182/blood-2003-07-2594. CrossRefPubMed

10.

Thijs J, Krastev T, Weidinger S, Buckens CF, de Bruin-Weller M, Bruijnzeel-Koomen C, et al. Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Curr Opin Allergy Clin Immunol. 2015;15(5):453–60. https://doi.org/10.1097/ACI.0000000000000198. CrossRefPubMed

11.

Dulmage B, Geskin L, Guitart J, Akilov OE. The biomarker landscape in mycosis fungoides and Sézary syndrome. Exp Dermatol. 2017;26(8):668–76. https://doi.org/10.1111/exd.13261. CrossRefPubMedPubMedCentral

12.

Vermeer MH, Dukers DF, ten Berge RL, Bloemena E, Wu L, Vos W, et al. Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin’s disease. Mod Pathol. 2002;15(8):838–44. https://doi.org/10.1097/01.MP.0000021006.53593.B0. CrossRefPubMed

13.

Weihrauch MR, Manzke O, Beyer M, Haverkamp H, Diehl V, Bohlen H, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin’s disease: potential for a prognostic factor. Cancer Res. 2005;65(13):5516–9. https://doi.org/10.1158/0008-5472.CAN-05-0100. CrossRefPubMed

14.

Plattel WJ, van den Berg A, Visser L, van der Graaf AM, Pruim J, Vos H, et al. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin’s lymphoma. Haematologica. 2012;97(3):410–5. https://doi.org/10.3324/haematol.2011.053199. CrossRefPubMedPubMedCentral

15.

Sauer M, Plütschow A, Jachimowicz RD, Kleefisch D, Reiners KS, Ponader S, et al. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol. 2013;88(2):113–5. https://doi.org/10.1002/ajh.23361. CrossRefPubMed

16.

Jones K, Vari F, Keane C, Crooks P, Nourse JP, Seymour LA, et al. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res. 2013;19(3):731–42. https://doi.org/10.1158/1078-0432.CCR-12-2693. CrossRefPubMed

17.

Harrison SJ, Hsu AK, Neeson P, Younes A, Sureda A, Engert A, et al. Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. Leuk Lymphoma. 2014;55(5):1053–60. https://doi.org/10.3109/10428194.2013.820287. CrossRefPubMed

18.

Farina L, Rezzonico F, Spina F, Dodero A, Mazzocchi A, Crippa F, et al. Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20(12):1982–8. https://doi.org/10.1016/j.bbmt.2014.08.016. CrossRefPubMed

19.

Cuccaro A, Annunziata S, Cupelli E, Martini M, Calcagni ML, Rufini V, et al. CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. Cancer Med. 2016;5(3):398–406. https://doi.org/10.1002/cam4.585. CrossRefPubMedPubMedCentral

20.

Plattel WJ, Alsada ZN, van Imhoff GW, Diepstra A, van den Berg A, Visser L. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin‑1, sCD163 and sCD30 with TARC. Br J Haematol. 2016;175(5):868–75. https://doi.org/10.1111/bjh.14317. CrossRefPubMed

21.

Guidetti A, Mazzocchi A, Miceli R, Paterno’ E, Taverna F, Spina F, et al. Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin lymphoma. Leuk Res. 2017;62:91–7. https://doi.org/10.1016/j.leukres.2017.09.018. CrossRefPubMed

22.

Moskowitz AJ, Schöder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017;130(20):2196–203. https://doi.org/10.1182/blood-2017-06-788877. CrossRefPubMedPubMedCentral

23.

Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, et al. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood. 2019;133(16):1762–5. https://doi.org/10.1182/blood-2018-08-870915. CrossRefPubMedPubMedCentral

24.

Plattel WJ, Visser L, Diepstra A, Glaudemans AWJM, Nijland M, van Meerten T, et al. Interim thymus and activation regulated chemokine versus interim ¹⁸ F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation. Br J Haematol. 2020;190(1):40–4. https://doi.org/10.1111/bjh.16514. CrossRefPubMedPubMedCentral

25.

Viviani S, Mazzocchi A, Pavoni C, Taverna F, Rossi A, Patti C, et al. Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy. Hematol Oncol. 2020;38(4):501–8. https://doi.org/10.1002/hon.2775. CrossRefPubMed

26.

Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis. Br J Haematol. 2015;170(3):356–66. https://doi.org/10.1111/bjh.13441. CrossRefPubMed

27.

Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99(6):1107–13. https://doi.org/10.3324/haematol.2013.103218. CrossRefPubMedPubMedCentral

28.

Zijtregtop EAM, Meyer-Wentrup F, Wong W‑C, et al. Plasma thymus and activation-regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma. eJHaem. 2020;1:152–60. https://doi.org/10.1002/jha2.41. CrossRef

29.

Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851–62. https://doi.org/10.1084/jem.20031074. CrossRefPubMedPubMedCentral

30.

Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood. 2008;112(4):1424–33. https://doi.org/10.1182/blood-2008-01-133769. CrossRefPubMedPubMedCentral

31.

Yonekura K, Kusumoto S, Choi I, Nakano N, Ito A, Suehiro Y, et al. Mogamulizumab for adult T‑cell leukemia-lymphoma: a multicenter prospective observational study. Blood Adv. 2020;4(20):5133–45. https://doi.org/10.1182/bloodadvances.2020003053. CrossRefPubMedPubMedCentral

Titel: Is thymus and activation-regulated chemokine a forgotten diagnostic and minimal residual disease marker in classical Hodgkin lymphoma?
A chronological narrative literature review
verfasst von: Wael Khair, MD
Publikationsdatum: 04.10.2021
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00753-x

Home

Zeitschriften

Zeitungen

Podcast

Gesundheitspolitik

Praxis

Leben

Jobs

Fachgebiete

Subfächer Innere Medizin

Fortbildungen

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Is thymus and activation-regulated chemokine a forgotten diagnostic and minimal residual disease marker in classical Hodgkin lymphoma?

A chronological narrative literature review

Summary

Objective

Background

Methods

Conclusion

Fachgebiete

Subfächer Innere Medizin

Fortbildungen

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Objective

Background

Methods

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Practical considerations for the management of immune thrombocytopenic purpura

Rare lung cancers—2021 update on challenges, advances, and opportunities

Best of ASCO 2021: new data from triple-negative breast cancer

Practical issues in hematology

Unresectable pleural mesothelioma—hope or still an unmet medical need?

Best of ASCO 2021—bladder cancer